Hypertensive disorders of pregnancy (HDP) are more common in pregnant women with systemic lupus erythematosus than those without the chronic autoimmune disease, and pose an increased risk of heart disease and high blood pressure later in life, a large Swedish study shows. The study, “Maternal hypertensive…
The Lupus Foundation of America (LFA) is partnering with Lupus Canada to fund the Lupus Canada Catalyst Award that supports research projects with potential to advance the field and improve the lives of people living with lupus. The award will be given to one researcher (a…
A newly identified genetic signature may provide clues into the mechanisms underlying systemic lupus erythematosus (SLE), and open new potential avenues to personalized treatments. The research, “Integrated, multi-cohort analysis reveals unified signature of systemic lupus erythematosus,” was published in the journal JCI Insight. Gene expression…
Two comprehensive tools can reliably measure changes in disease activity in people with systemic lupus erythematosus (SLE), a new study suggests. The findings support the use of these instruments — the SELENA SLEDAI Physician’s Global Assessment, known as the SSPGA, and the Lupus Foundation of America-Rapid Evaluation of Activity…
Exposure to dust and having post-traumatic stress disorder (PTSD) as a result of the 9/11 terrorist attacks in New York are associated with an increased risk of developing autoimmune diseases such as systemic lupus erythematosus, a study reports. This finding highlights the need for better monitoring of the…
Physical and emotional abuse during childhood may increase the risk of developing systemic lupus erythematosus (SLE) later in life, a new study has found. The study, “Association of Childhood Abuse with Incident Systemic Lupus Erythematosus in Adulthood in a Longitudinal Cohort of Women,” was published in …
Fatigue has a major impact on quality of life in people with systemic lupus erythematosus, and measuring it using a patient-reported tool may prove useful in clinical trials, new research shows. The findings were presented at the recent 2019 American College of Rheumatology/Association for Rheumatology Professionals Annual Meeting…
Adding investigational anifrolumab to standard therapy lowers disease activity, limits the need for corticosteroids, and eases skin symptoms in people with moderate to severe systemic lupus erythematosus (SLE), a Phase 3 clinical trial shows. Trial results were discussed in a presentation titled “A Phase 3…
Adding low-dose interleukin-2 (IL-2) to standard therapy increases responses and complete remission of lupus nephritis in patients with systemic lupus erythematosus (SLE), results of a randomized clinical trial suggest. Patients on IL-2 had higher proportions of regulatory T cells, a subset of immune T cells associated with…
Despite limited evidence that opioids reduce pain in people with rheumatic diseases, a study has found that nearly one in three adults with systemic lupus erythematosus (SLE) use prescription opioids for pain control, with two-thirds of them using these medications for longer than one year. The study, “…